Amgen

Yahoo Finance • 16 hours ago

Renal Cell Carcinoma Market Report 2026-2030 & 2035: Increasing Immunotherapy and Precision Oncology Programs Drives Market Expansion, Reaching USD 6.09 Billion by 2030

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Renal Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive analysis, depicting global market size, regional shares,... Full story

Yahoo Finance • 2 days ago

Merck oral PCSK9 enlicitide shows improved cholesterol lowering vs. non-statins

[Merck headquarters in Kenilworth, New Jersey, August 23, 2022.] JHVEPhoto * New phase 3 data found that Merck's oral PCSK9 inhibitor, enlicitide decanoate, led to greater lowering of low-density lipoprotein cholesterol (LDL-C) compared... Full story

Yahoo Finance • 2 days ago

Viridian Therapeutics Crashes On 'Positive, But Lackluster' Thyroid Eye Disease Results

Viridian Therapeutics stock crashed Monday on "positive, but lackluster" final-phase results for its thyroid eye disease treatment. Continue Reading... Full story

Yahoo Finance • 2 days ago

How Merck's New Cholesterol Buster Will 'Move The Needle' 'By Removing The Needle'

Merck's experimental cholesterol buster easily outperformed a triplet of medications, the Dow Jones component said Monday. Continue Reading... Full story

Yahoo Finance • 2 days ago

Teva gains approval of biosimilar of Amgen's Prolia

[Teva Canada Markham manufacturing facility, Ontario, Canada.] JHVEPhoto * The US FDA has approved Teva Pharmaceutical Industries' (TEVA [https://seekingalpha.com/symbol/TEVA]) Ponlimsi (denosumab-adet), a biosimilar to Amgen's (AMGN [h... Full story

Yahoo Finance • 3 days ago

This Top ETF Recently Added a Healthy Dose of These High-Yielding Dividend Stocks

Key Points The Schwab U.S. Dividend Equity ETF recently completed its annual reconstitution. It added two new healthcare stocks to its top 10. Healthcare is now its second-largest sector. 10 stocks we like better than Schwab U.S. Dividend... Full story

Yahoo Finance • 3 days ago

Recurrent Head and Neck Cancer Squamous Cell Carcinoma Markets and Competition Outlook 2026-2030: Personalized Medicine Drives Revenue Growth, Reaching $4.61 Billion by 2030

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers comprehensive insights on market size, reg... Full story

Yahoo Finance • 5 days ago

Wells Fargo Raises Vertex Pharmaceuticals (VRTX) Price Target to $550

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 15 Set-It-and-Forget-It Stocks to Buy in 2026.Wells Fargo Raises Vertex Pharmaceuticals (VRTX) Price Target to $550 On March 19, 2026, Vertex Pharmaceuticals Incorporated (NA... Full story

Yahoo Finance • 5 days ago

Anti-Cancer MAbS Market Report 2026-2030 Featuring Strategic Analysis of Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, Roche, GlaxoSmithKline and Other Key Players

Company Logo Opportunities in the anti-cancer mAbs market include growth in personalized cancer medicine, expansion of biosimilar mAbs, and increased oncology spending Anti-Cancer MAbS MarketAnti-Cancer MAbS Market·GlobeNewswire Inc. Du... Full story

Yahoo Finance • 5 days ago

Clinical Nutrition for Diabetes Care Market Report 2026-2030 Featuring Profiles of Key Players - Pfizer, Bayer, Sanofi-Aventis, Abbott Labs, Roche and More

Company Logo The rise of diabetes, demand for specialized nutrition, digital monitoring tools, and home-based management are key trends driving market growth Clinical Nutrition for Diabetes Care MarketClinical Nutrition for Diabetes Care... Full story

Yahoo Finance • 6 days ago

SK pharmteco to Host Innovations in Pharmaceutical Manufacturing Symposium in Cambridge, Massachusetts

SK pharmteco Inc. Innovations in Pharmaceutical Manufacturing: Continuous Manufacturing, Advanced Processing & Scalable Technologies on April 8th to feature top experts RANCHO CORDOVA, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- SK pharmt... Full story

Yahoo Finance • 7 days ago

SCHD Annual Reconstitution: Here's What This Dividend ETF Looks Like Now

Every year in March, the Schwab U.S. Dividend Equity ETF(NYSEMKT: SCHD) reconstitutes and rebalances itself. This essentially means that it runs its strategic methodology from scratch and rebuilds its portfolio according to what's happenin... Full story

Yahoo Finance • 8 days ago

Wells Fargo Raises its Price Target on Amgen (AMGN) to $390 from $375

Amgen Inc. (NASDAQ:AMGN) is one of the 10 Most Profitable S&P 500 Stocks to Buy Now. On March 19, 2026, Wells Fargo raised the price target on Amgen Inc. (NASDAQ:AMGN) to $390 from $375 and maintained an Equal Weight rating. The firm high... Full story

Yahoo Finance • 9 days ago

Barron's 400 ETF (BFOR) Adds Energy and Utilities, Cuts Back on Consumer Discretionary and Materials in Spring Rebalance

DENVER, March 23, 2026--(BUSINESS WIRE)--The Barron’s 400 ETF (NYSE Arca: BFOR, the "Fund"), a smart beta exchange-traded fund, has completed its semi-annual rebalance following the reconstitution and equal weighting of its underlying benc... Full story

Yahoo Finance • 11 days ago

Notable healthcare headlines for the week: Eli Lilly, Novo Nordisk, and Novartis in focus

Wall Street's major averages closed deep in the red on Friday, with oil sustaining higher prices even as Israeli Prime Minister Netanyahu said the country is helping to reopen the Strait of Hormuz. The benchmark S&P 500 ended -1.5%, while... Full story

Yahoo Finance • 17 days ago

Amgen Inc. (AMGN) Collaborates on Ending Anti-OX40 Clinical Studies

We recently compiled a list of the 11 Best Kid-Friendly Stocks to Invest In. Amgen Inc. (NASDAQ:AMGN) is one of the best kid-friendly stocks on our list. On March 3, TheFly reported that Kyowa Kirin Co., Ltd. disclosed that it is disconti... Full story

Yahoo Finance • 17 days ago

Amgen’s TrumpRx Discounts and Dividend Hike Might Change The Case For Investing In Amgen (AMGN)

In early March 2026, Amgen announced a US$2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs such as Amjevita, Aimovig, and Repatha, while also preparing for its March 11 present... Full story

Yahoo Finance • 18 days ago

Amgen and GSK said to be adding products on TrumpRx

[Prescription Medicine Bottles and Pills Next To Stacks of 100 Dollar Bills.] Feverpitched/iStock via Getty Images Amgen (AMGN [https://seekingalpha.com/symbol/AMGN]) and GSK (GSK [https://seekingalpha.com/symbol/GSK]) will be the latest... Full story

Yahoo Finance • 19 days ago

2 Mega-Cap Stocks to Keep an Eye On and 1 Facing Headwinds

Megacap stocks are behemoths that set the tone for their industries, and their massive scale typically leads to wide moats. However, the downside is that most have already exploited their existing market opportunities and must invest heavi... Full story

Yahoo Finance • 20 days ago

Rapid Micro Biosystems, Inc. Q4 2025 Earnings Call Summary

Rapid Micro Biosystems, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Performance and Operational Context Achieved record fourth quarter revenue of $11.3 million, representing 37% year-over-year growth and the 13th consecutive quar... Full story